MedKoo product information:

 Azacitidine

azacitidine is a pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation. Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

According to http://en.wikipedia.org/wiki/Azacitidine, Azacitidine is mainly used in the treatment of myelodysplastic syndrome (MDS), for which it received approval by the U.S. Food and Drug Administration on May 19, 2004; it is marketed as Vidaza. In a randomized controlled trial comparing azacitidine to supportive treatment of MDS, around 16% of people receiving the drug had a complete or partial response—blood cell counts and bone marrow morphology returning to normal—and 2/3 patients who required blood transfusions before the study no longer needed them after receiving azacitidine. It can also be used in vitro to remove methyl groups from DNA. This may weaken the effects of gene silencing mechanisms that occurred prior to the methylation. Methylation events are therefore believed to secure the DNA in a silenced state. Demethylation may reduce the stability of silencing signals and thus confer relative gene activation.

DRUG DESCRIPTION

VIDAZA (azacitidine for injection) contains azacitidine, which is a pyrimidine nucleoside analog of cytidine. Azacitidine is 4-amino-1-β-D-ribofuranosyl-s-triazin-2(1H)-one.  The empirical formula is C8H12N4O5. The molecular weight is 244. Azacitidine is a white to off- white solid. Azacitidine was found to be insoluble in acetone, ethanol, and methyl ethyl ketone; slightly soluble in ethanol/water (50/50), propylene glycol, and polyethylene glycol; sparingly soluble in water, water saturated octanol, 5% dextrose in water, N-methyl-2-pyrrolidone, normal saline and 5% Tween 80 in water; and soluble in dimethylsulfoxide (DMSO). The finished product is supplied in a sterile form for reconstitution as a suspension for subcutaneous injection or reconstitution as a solution with further dilution for intravenous infusion. Vials of VIDAZA contain 100 mg of azacitidine and 100 mg mannitol as a sterile lyophilized powder.

Mechanism of Action

VIDAZA is a pyrimidine nucleoside analog of cytidine. VIDAZA is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of azacitidine required for maximum inhibition of DNA methylationin vitro does not cause major suppression of DNA synthesis. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of azacitidine cause the death of rapidly dividing cells, including cancer cells that are no longer responsive to normal growth control mechanisms. Non-proliferating cells are relatively insensitive to azacitidine.

 1: Mittelman M, Oster HS, Hoffman M, Neumann D. The lower risk MDS patient at risk of rapid progression. Leuk Res. 2010 Jun 21. [Epub ahead of print] PubMed PMID: 20573398.

2: Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Ann Hematol. 2010 Jun 22. [Epub ahead of print] PubMed PMID: 20567826.

3: Quintás-Cardama A, Santos FP, Garcia-Manero G; Medscape. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol. 2010 Jun 15. [Epub ahead of print] PubMed PMID: 20551943.

4: Bauer K, Herbst C, Brillant C, Monsef I, Kluge S, Skoetz N, Engert A. Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma. J Natl Cancer Inst. 2010 Jun 16;102(12):E1. PubMed PMID: 20551424.

5: Galili N, Raza A. Pharmacotherapy of myelodysplastic syndromes. Expert Opin Pharmacother. 2010 May 20. [Epub ahead of print] PubMed PMID: 20486832.

6: Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR, Dipersio JF. In vivo administration of hypomethylating agents mitigate graft-versus-host disease (GvHD) without sacrificing graft-versus-leukemia (GvL). Blood. 2010 Apr 27. [Epub ahead of print] PubMed PMID: 20424188.

7: Zhu X, Ma Y, Liu D. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol. 2010 Apr 23;3:17. PubMed PMID: 20416083; PubMed Central PMCID: PMC2880983.

8: Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LR, List A, Gore SD, Seymour JF, Backstrom J, Beach CL. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol. 2010 Apr 12. [Epub ahead of print] PubMed PMID: 20394651.

9: Cang S, Lu Q, Ma Y, Liu D. Clinical advances in hypomethylating agents targeting epigenetic pathways. Curr Cancer Drug Targets. 2010 Aug;10(5):539-45. PubMed PMID: 20384584.

10: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jan-Feb;32(1):47-86. PubMed PMID: 20383346.

11: Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jäger E, Lübbert M. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. 2010 Jul;34(7):899-905. Epub 2010 Apr 10. PubMed PMID: 20381863.

12: Steensma DP, Stone RM. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010 Apr;24(2):389-406. Review. PubMed PMID: 20359633.

13: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Nov;31(9):597-633. PubMed PMID: 20094643.

14: Kogan AJ, Dunn JD. Myelodysplastic syndromes: health care management considerations. Manag Care. 2009 Nov;18(11 Suppl 9):25-8; discussion 28-9. PubMed PMID: 20085114.

15: Müller A, Florek M. 5-Azacytidine/Azacitidine. Recent Results Cancer Res. 2010;184:159-70. Review. PubMed PMID: 20072837.

16: Daskalakis M, Blagitko-Dorfs N, Hackanson B. Decitabine. Recent Results Cancer Res. 2010;184:131-57. Review. PubMed PMID: 20072836.

17: Krug U, Lübbert M, Büchner T. Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest? Curr Opin Hematol. 2010 Mar;17(2):85-90. Review. PubMed PMID: 20061945.

18: Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010 Jan;10(1):9-22. Review. PubMed PMID: 20014881.

19: Sekeres MA. Treatment of MDS: something old, something new, something borrowed... Hematology Am Soc Hematol Educ Program. 2009:656-63. Review. PubMed PMID: 20008251.

20: Fenaux P, Ades L. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes. Leuk Res. 2009 Dec;33 Suppl 2:S7-11. Review. PubMed PMID: 20004796.

21: Gore SD. In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment? Leuk Res. 2009 Dec;33 Suppl 2:S2-6. PubMed PMID: 20004793.

22: Steensma DP. Decitabine treatment of patients with higher-risk myelodysplastic syndromes. Leuk Res. 2009 Dec;33 Suppl 2:S12-7. PubMed PMID: 20004791.

23: Stone R, Sekeres M, Garcia-Manero G. Evolving strategies in the treatment of MDS and AML. Clin Adv Hematol Oncol. 2009 Aug;7(8):1-14; quiz 2 p following 14. PubMed PMID: 19927982.

24: Ishikawa T. [Novel therapeutic agents for myelodysplastic syndrome]. Rinsho Ketsueki. 2009 Oct;50(10):1553-9. Review. Japanese. PubMed PMID: 19915366.

25: Keating GM. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. Drugs. 2009;69(17):2501-18. doi: 10.2165/11202840-000000000-00000. Review. PubMed PMID: 19911860.

26: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Sep;31(7):463-93. PubMed PMID: 19907722.

27: Koninckx R, Hensen K, Daniëls A, Moreels M, Lambrichts I, Jongen H, Clijsters C, Mees U, Steels P, Hendrikx M, Rummens JL. Human bone marrow stem cells co-cultured with neonatal rat cardiomyocytes display limited cardiomyogenic plasticity. Cytotherapy. 2009;11(6):778-92. PubMed PMID: 19878064.

28: Yokoyama H, Harigae H. [Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia]. Nippon Rinsho. 2009 Oct;67(10):1974-7. Review. Japanese. PubMed PMID: 19860200.

29: Kumar A, List AF, Hozo I, Komrokji R, Djulbegovic B. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica. 2010 Feb;95(2):340-2; author reply 343-4. Epub 2009 Oct 22. PubMed PMID: 19850902; PubMed Central PMCID: PMC2817042.

30: Dombret H, Raffoux E, Gardin C. New insights in the management of elderly patients with acute myeloid leukemia. Curr Opin Oncol. 2009 Nov;21(6):589-93. Review. PubMed PMID: 19812493.

31: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jul-Aug;31(6):397-417. PubMed PMID: 19798455.

32: Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P, Shpilberg O. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis. Haematologica. 2010 Feb;95(2):303-10. Epub 2009 Sep 22. PubMed PMID: 19773261; PubMed Central PMCID: PMC2817034.

33: Tuma RS. Epigenetic therapies move into new territory, but how exactly do they work? J Natl Cancer Inst. 2009 Oct 7;101(19):1300-1. Epub 2009 Sep 15. PubMed PMID: 19755677.

34: Scott BL. Clinical roundtable monograph. Combination therapies for MDS. Clin Adv Hematol Oncol. 2009 Jul;7(7):S13-5. PubMed PMID: 19731466.

35: Silverman LR. Clinical roundtable monograph. Overall survival and maintenance of MDS patients. Clin Adv Hematol Oncol. 2009 Jul;7(7):S3-5. PubMed PMID: 19708287.

36: Rose MG. Hematology: Azacitidine improves survival in myelodysplastic syndromes. Nat Rev Clin Oncol. 2009 Sep;6(9):502-3. PubMed PMID: 19707240.

37: Li Q, Bartlett DL, Gorry MC, O'Malley ME, Guo ZS. Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. Mol Pharmacol. 2009 Nov;76(5):1072-81. Epub 2009 Aug 13. PubMed PMID: 19679824.

38: Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2009 Sep;84(9):599-600. PubMed PMID: 19650144.

39: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jun;31(5):341-56. PubMed PMID: 19649342.

40: Cataldo VD, Cortes J, Quintás-Cardama A. Azacitidine for the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther. 2009 Jul;9(7):875-84. Review. PubMed PMID: 19589026.

41: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 May;31(4):263-98. PubMed PMID: 19557204.

42: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Apr;31(3):183-226. PubMed PMID: 19536362.

43: Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res. 2009 Jun 15;15(12):3938-46. Epub 2009 Jun 9. PubMed PMID: 19509174; PubMed Central PMCID: PMC2732562.

44: Hemavathy K, Wang JC. Epigenetic modifications: new therapeutic targets in primary myelofibrosis. Curr Stem Cell Res Ther. 2009 Dec;4(4):281-6. Review. PubMed PMID: 19500065.

45: Rogstad DK, Herring JL, Theruvathu JA, Burdzy A, Perry CC, Neidigh JW, Sowers LC. Chemical decomposition of 5-aza-2'-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol. 2009 Jun;22(6):1194-204. PubMed PMID: 19480391.

46: Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics. 2009 Apr;4(3):176-84. Epub 2009 Apr 6. PubMed PMID: 19421002; PubMed Central PMCID: PMC2848123.

47: Stone R, Sekeres M, Garcia-Manero G, Lyons RM. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. Clin Adv Hematol Oncol. 2008 Dec;6(12):1-15. PubMed PMID: 19385003.

48: Stone RM. How I treat patients with myelodysplastic syndromes. Blood. 2009 Jun 18;113(25):6296-303. Epub 2009 Apr 21. Review. PubMed PMID: 19383969.

49: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57. PubMed PMID: 19357798.

50: Tomillero A, Moral MA. Gateways to clinical trials. December 2008. Methods Find Exp Clin Pharmacol. 2008 Dec;30(10):761-82. PubMed PMID: 19271026.

51: Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, Lübbert M. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28. Epub 2009 Feb 5. PubMed PMID: 19194470.

52: Festuccia C, Gravina GL, D'Alessandro AM, Muzi P, Millimaggi D, Dolo V, Ricevuto E, Vicentini C, Bologna M. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer. 2009 Jun;16(2):401-13. Epub 2009 Jan 19. PubMed PMID: 19153211.

53: Scott BL, Estey E. Management of myelodysplastic syndromes: 2008 update. Oncology (Williston Park). 2008 Nov 15;22(12):1344-52. Review. PubMed PMID: 19086598; PubMed Central PMCID: PMC2647329.

54: Trompeter S, Roberts I. Haemoglobin F modulation in childhood sickle cell disease. Br J Haematol. 2009 Feb;144(3):308-16. Epub 2008 Nov 20. Review. PubMed PMID: 19036119.

55: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88. PubMed PMID: 18985183.

56: Gore SD, Hermes-DeSantis ER. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control. 2008 Oct;15 Suppl:40-9. Review. PubMed PMID: 18813208; PubMed Central PMCID: PMC2727156.

57: List AF. Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes. Cancer Control. 2008 Oct;15 Suppl:29-39. PubMed PMID: 18813207.

58: Mufti GJ, Chen TL. Changing the treatment paradigm in myelodysplastic syndromes. Cancer Control. 2008 Oct;15 Suppl:14-28. Review. PubMed PMID: 18813206.

59: Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol. 2008 Nov;20(6):705-10. Review. PubMed PMID: 18841054.

60: Miyazawa K. [Pathogenesis of and therapeutic progress for myelodysplastic syndromes]. Rinsho Ketsueki. 2008 Oct;49(10):1358-67. Review. Japanese. PubMed PMID: 18833920.

61: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408. PubMed PMID: 18806898.

62: Müller-Thomas C, Schuster T, Peschel C, Götze KS. A limited number of 5-azacitidine cycles can be effective treatment in MDS. Ann Hematol. 2009 Mar;88(3):213-9. Epub 2008 Aug 12. PubMed PMID: 18696067.

63: Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. Int J Oncol. 2008 Aug;33(2):381-8. PubMed PMID: 18636160.

64: O'Dwyer K, Maslak P. Azacitidine and the beginnings of therapeutic epigenetic modulation. Expert Opin Pharmacother. 2008 Aug;9(11):1981-6. Review. PubMed PMID: 18627335.

65: Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S. A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep;22(9):1680-4. Epub 2008 Jun 12. PubMed PMID: 18548103.

66: Oki Y, Issa JP. Review: recent clinical trials in epigenetic therapy. Rev Recent Clin Trials. 2006 May;1(2):169-82. Review. PubMed PMID: 18473969.

67: Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. BMC Cancer. 2008 May 2;8:128. PubMed PMID: 18454857; PubMed Central PMCID: PMC2386792.

68: Craig CM, Schiller GJ. Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. Blood Rev. 2008 Jul;22(4):221-34. Epub 2008 Apr 22. Review. PubMed PMID: 18433953.

69: Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun;112(11):2341-51. Review. PubMed PMID: 18398832.

70: Kuendgen A, Lübbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol. 2008 Aug;87(8):601-11. Epub 2008 Apr 5. Review. PubMed PMID: 18392623.

71: Garcia-Manero G, Yang AS, Jagasia M. Evaluating new treatment options for MDS. Clin Adv Hematol Oncol. 2007 Nov;5(11):1-9; quiz 10-2. Review. PubMed PMID: 18185491.

72: Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol. 2008 Jan;45(1):23-30. Review. PubMed PMID: 18179966; PubMed Central PMCID: PMC2234265.

73: Abdulhaq H, Rossetti JM. The role of azacitidine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs. 2007 Dec;16(12):1967-75. Review. PubMed PMID: 18042004.

74: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83. PubMed PMID: 18040531.

75: Gao S, Mobley A, Miller C, Boklan J, Chandra J. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leuk Res. 2008 May;32(5):771-80. Epub 2007 Nov 26. PubMed PMID: 18031811; PubMed Central PMCID: PMC2320596.

76: Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schätzlein A, Twelves C, Kaye SB, Brown R. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007 Oct 10;25(29):4603-9. PubMed PMID: 17925555.

77: Plimack ER, Stewart DJ, Issa JP. Combining epigenetic and cytotoxic therapy in the treatment of solid tumors. J Clin Oncol. 2007 Oct 10;25(29):4519-21. PubMed PMID: 17925545.

78: Allen A. Epigenetic alterations and cancer: new targets for therapy. IDrugs. 2007 Oct;10(10):709-12. Review. PubMed PMID: 17899489.

79: Wijermans PW, Rüter B, Baer MR, Slack JL, Saba HI, Lübbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008 Apr;32(4):587-91. Epub 2007 Sep 18. PubMed PMID: 17881052.

80: Kihslinger JE, Godley LA. The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma. 2007 Sep;48(9):1676-95. Review. PubMed PMID: 17786703.

81: Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma. 2007 Aug;48(8):1472-81. Review. PubMed PMID: 17701577.

82: Lavelle D, Chin J, Vaitkus K, Redkar S, Phiasivongsa P, Tang C, Will R, Hankewych M, Roxas B, Singh M, Saunthararajah Y, Desimone J. Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis. Am J Hematol. 2007 Nov;82(11):981-5. PubMed PMID: 17696208.

83: Atallah E, Garcia-Manero G. Use of hypomethylating agents in myelodysplastic syndromes. Clin Adv Hematol Oncol. 2007 Jul;5(7):544-52. Review. PubMed PMID: 17679928.

84: Giagounidis AA. Decitabine dosage in myelodysplastic syndromes. Blood. 2007 Aug 1;110(3):1082-3; author reply 1083. PubMed PMID: 17644750.

85: Rüter B, Wijermans P, Claus R, Kunzmann R, Lübbert M. Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood. 2007 Aug 1;110(3):1080-2; author reply 1083. PubMed PMID: 17644749.

86: Ghoshal K, Bai S. DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc). 2007 Jun;43(6):395-422. Review. PubMed PMID: 17612710.

87: Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007 May 10;25(14):1908-15. Review. PubMed PMID: 17488990.

88: Brueckner B, Kuck D, Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J. 2007 Jan-Feb;13(1):17-22. Review. PubMed PMID: 17464242.

89: Braun TM, Thall PF, Nguyen H, de Lima M. Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clin Trials. 2007;4(2):113-24. PubMed PMID: 17456511.

90: Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthein R, Wehrmann M, Gregor M, Lauer UM, Bitzer M. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer. 2007 May 15;109(10):2132-41. PubMed PMID: 17407132.

91: Shadduck RK, Latsko JM, Rossetti JM, Haq B, Abdulhaq H. Recent advances in myelodysplastic syndromes. Exp Hematol. 2007 Apr;35(4 Suppl 1):137-43. Review. PubMed PMID: 17379099.

92: Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007 Mar 15;13(6):1634-7. Review. PubMed PMID: 17363514.

93: Schiffer CA. Myelodysplasia: the good, the fair and the ugly. Best Pract Res Clin Haematol. 2007 Mar;20(1):49-55. Review. PubMed PMID: 17336254.

94: Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers. 2007;23(1-2):73-87. Review. PubMed PMID: 17325427.

95: Liu Z, Liu S, Xie Z, Blum W, Perrotti D, Paschka P, Klisovic R, Byrd J, Chan KK, Marcucci G. Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic Acids Res. 2007;35(5):e31. Epub 2007 Jan 30. PubMed PMID: 17264127; PubMed Central PMCID: PMC1865075.

96: Egger G, Aparicio AM, Escobar SG, Jones PA. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res. 2007 Jan 1;67(1):346-53. PubMed PMID: 17210717.

97: Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother. 2007 Jan;8(1):65-73. Review. PubMed PMID: 17163808.

98: Raza A, Raza FZ, Galili N. Low-dose decitabine and high-risk MDS. Blood. 2006 Dec 15;108(13):4291; author reply 4291-2. PubMed PMID: 17148594.

99: Fathallah H, Atweh GF. Induction of fetal hemoglobin in the treatment of sickle cell disease. Hematology Am Soc Hematol Educ Program. 2006:58-62. Review. PubMed PMID: 17124041.

100: Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31. Epub 2006 Nov 6. PubMed PMID: 17088539; PubMed Central PMCID: PMC1859945.

101: Balaian L, Ball ED. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia. 2006 Dec;20(12):2093-101. Epub 2006 Oct 19. PubMed PMID: 17051243.

102: Mack GS. Epigenetic cancer therapy makes headway. J Natl Cancer Inst. 2006 Oct 18;98(20):1443-4. PubMed PMID: 17047192.

103: Oki Y, Aoki E, Issa JP. Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. Epub 2006 Oct 4. Review. PubMed PMID: 17023173.

104: Meletis J, Viniou N, Terpos E. Novel agents for the management of myelodysplastic syndromes. Med Sci Monit. 2006 Sep;12(9):RA194-206. Review. PubMed PMID: 16940944.

105: Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA; Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20;24(24):3895-903. PubMed PMID: 16921040.

106: Hurtubise A, Momparler RL. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother Pharmacol. 2006 Nov;58(5):618-25. Epub 2006 Jun 17. PubMed PMID: 16783580.

107: Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006 Jun 15;66(12):6361-9. PubMed PMID: 16778214.

108: Kantarjian HM, Cortes J. New strategies in chronic myeloid leukemia. Int J Hematol. 2006 May;83(4):289-93. Review. PubMed PMID: 16757426.

109: Garcia-Manero G, Saba HI. Decitabine in myelodysplastic syndromes: viewpoints. Drugs. 2006;66(7):959-60. PubMed PMID: 16740015.

110: McKeage K, Croom KF. Decitabine: in myelodysplastic syndromes. Drugs. 2006;66(7):951-8. PubMed PMID: 16740014.

111: Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol. 2006 Jun 1;24(16):2576-82. Review. PubMed PMID: 16735711.

112: Wijermans P, Lübert M. Epigenetic therapy with decitabine for myelodysplasia and leukemia. Future Oncol. 2005 Oct;1(5):585-91. Review. PubMed PMID: 16556035.

113: Rüter B, Wijermans PW, Lübbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer. 2006 Apr 15;106(8):1744-50. PubMed PMID: 16532502.

114: Steinberg MH. Pathophysiologically based drug treatment of sickle cell disease. Trends Pharmacol Sci. 2006 Apr;27(4):204-10. Epub 2006 Mar 13. Review. PubMed PMID: 16530854.

115: List AF. New agents in the treatment of MDS. Clin Adv Hematol Oncol. 2005 Nov;3(11):832-4. PubMed PMID: 16491623.

116: Gore SD. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. J Natl Compr Canc Netw. 2006 Jan;4(1):83-90. Review. PubMed PMID: 16403407.

117: Fenaux P. Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S36-44. Review. PubMed PMID: 16341239.

118: Hackanson B, Robbel C, Wijermans P, Lübbert M. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. Ann Hematol. 2005 Dec;84 Suppl 1:32-8. Review. PubMed PMID: 16292549.

119: Yee KW, Jabbour E, Kantarjian HM, Giles FJ. Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Ann Hematol. 2005 Dec;84 Suppl 1:18-24. PubMed PMID: 16273408.

120: Rosenfeld CS. Clinical development of decitabine as a prototype for an epigenetic drug program. Semin Oncol. 2005 Oct;32(5):465-72. Review. PubMed PMID: 16210087.

121: Murgo AJ. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs. Semin Oncol. 2005 Oct;32(5):458-64. Review. PubMed PMID: 16210086.

122: Momparler RL. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). Semin Oncol. 2005 Oct;32(5):443-51. Review. PubMed PMID: 16210084.

123: Hubeek I, Peters GJ, Broekhuizen AJ, Sargent J, Gibson BE, Creutzig U, Kaspers GJ. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia. Br J Haematol. 2005 Oct;131(2):219-22. PubMed PMID: 16197453.

124: DeSimone J. Approaches to the reactivation of hemoglobin F as a treatment for sickle cell disease. Clin Adv Hematol Oncol. 2004 Jan;2(1):23-4. PubMed PMID: 16163154.

125: Haas PS, Wijermans P, Verhoef G, Lübbert M. Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability. Leuk Res. 2006 Mar;30(3):338-42. Epub 2005 Sep 12. PubMed PMID: 16162357.

126: Kuykendall JR. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Ann Pharmacother. 2005 Oct;39(10):1700-9. Epub 2005 Sep 6. Review. PubMed PMID: 16144884.

127: Demakos EP, Linebaugh JA. Advances in myelodysplastic syndrome: nursing implications of azacitidine. Clin J Oncol Nurs. 2005 Aug;9(4):417-23. Review. PubMed PMID: 16117208.

128: Siddiqui MA, Scott LJ. Azacitidine: in myelodysplastic syndromes. Drugs. 2005;65(13):1781-9; discussion 1790-1. Review. PubMed PMID: 16114977.

129: Sullivan M, Hahn K, Kolesar JM. Azacitidine: a novel agent for myelodysplastic syndromes. Am J Health Syst Pharm. 2005 Aug 1;62(15):1567-73. Review. PubMed PMID: 16030365.

130: Issa JP, Byrd JC. Decitabine in chronic leukemias. Semin Hematol. 2005 Jul;42(3 Suppl 2):S43-9. Review. PubMed PMID: 16015505.

131: Kantarjian HM, Issa JP. Decitabine dosing schedules. Semin Hematol. 2005 Jul;42(3 Suppl 2):S17-22. Review. Erratum in: Semin Hematol. 2005 Oct;42(4):274. PubMed PMID: 16015500.

132: Issa JP, Kantarjian H. Azacitidine. Nat Rev Drug Discov. 2005 May;Suppl:S6-7. Review. PubMed PMID: 15962522.

133: Jabbour EJ, Giles FJ. New agents in myelodysplastic syndromes. Curr Hematol Rep. 2005 May;4(3):191-9. Review. PubMed PMID: 15865871.

134: Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine. Nat Rev Drug Discov. 2005 Apr;4(4):275-6. PubMed PMID: 15861567.

135: Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD, Carducci MA, Baker SD. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol. 2005 Jun 10;23(17):3906-11. Epub 2005 Apr 25. PubMed PMID: 15851763.

136: Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005 Mar;10(3):176-82. Review. PubMed PMID: 15793220.

137: Steiner FA, Hong JA, Fischette MR, Beer DG, Guo ZS, Chen GA, Weiser TS, Kassis ES, Nguyen DM, Lee S, Trepel JB, Schrump DS. Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene. 2005 Mar 31;24(14):2386-97. PubMed PMID: 15735751.

138: Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res. 2004 Dec 15;64(24):9167-71. PubMed PMID: 15604288.

139: Arthur C. Decitabine. MGI Pharma Inc/SuperGen Inc. IDrugs. 2004 Dec;7(12):1113-32. Review. PubMed PMID: 15599805.

140: Szafraniec SI, Stachnik KJ, Skierski JS. New nucleoside analogs in the treatment of solid tumors. Acta Pol Pharm. 2004 Jul-Aug;61(4):297-305. Review. PubMed PMID: 15575597.

141: Zhao M, Rudek MA, He P, Hartke C, Gore S, Carducci MA, Baker SD. Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 25;813(1-2):81-8. PubMed PMID: 15556519.

142: Schneider-Stock R, Diab-Assef M, Rohrbeck A, Foltzer-Jourdainne C, Boltze C, Hartig R, Schönfeld P, Roessner A, Gali-Muhtasib H. 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. J Pharmacol Exp Ther. 2005 Feb;312(2):525-36. Epub 2004 Nov 16. PubMed PMID: 15547111.

143: DeBaun MR. Issues regarding study design for initial clinical trials using decitabine. Semin Hematol. 2004 Oct;41(4 Suppl 6):23-7. PubMed PMID: 15534854.

144: Lal A, Vichinsky E. The role of fetal hemoglobin-enhancing agents in thalassemia. Semin Hematol. 2004 Oct;41(4 Suppl 6):17-22. Review. PubMed PMID: 15534853.

145: Saunthararajah Y, Lavelle D, DeSimone J. DNA hypo-methylating agents and sickle cell disease. Br J Haematol. 2004 Sep;126(5):629-36. Review. PubMed PMID: 15327513.

146: Hurtubise A, Momparler RL. Evaluation of antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines. Anticancer Drugs. 2004 Feb;15(2):161-7. PubMed PMID: 15075673.

147: Suwanawiboon B, Sumida KN. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures. Hawaii Med J. 2004 Jan;63(1):14-6, 25. Review. PubMed PMID: 15011897.

148: Dowell JE, Minna JD. Cancer chemotherapy targeted at reactivating the expression of epigenetically inactivated genes. J Clin Oncol. 2004 Apr 15;22(8):1353-5. Epub 2004 Mar 8. PubMed PMID: 15007082.

149: Lyons J, Bayar E, Fine G, McCullar M, Rolens R, Rubinfeld J, Rosenfeld C. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. Curr Opin Investig Drugs. 2003 Dec;4(12):1442-50. Review. PubMed PMID: 14763130.

150: Hennessy BT, Garcia-Manero G, Kantarjian HM, Giles FJ. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs. 2003 Dec;12(12):1985-93. Review. PubMed PMID: 14640942.

151: Issa JP. Decitabine. Curr Opin Oncol. 2003 Nov;15(6):446-51. Review. PubMed PMID: 14624227.

152: Leone G, Voso MT, Teofili L, Lübbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol. 2003 Oct;109(1):89-102. Review. PubMed PMID: 14585280.

153: Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716. Drugs R D. 2003;4(6):352-8. Review. PubMed PMID: 14584964.

154: Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716. Drugs R D. 2003;4(3):179-84. Review. PubMed PMID: 12757405.

155: Hirschfeld S, Ho PT, Smith M, Pazdur R. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. J Clin Oncol. 2003 Mar 15;21(6):1066-73. Epub 2003 Feb 7. Review. PubMed PMID: 12637472.

156: Shaker S, Bernstein M, Momparler LF, Momparler RL. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res. 2003 May;27(5):437-44. PubMed PMID: 12620295.

157: Decitabine has promising clinical activity in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2002 Dec;2(6):620-1. PubMed PMID: 12503205.

158: Primeau M, Gagnon J, Momparler RL. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer. 2003 Jan 10;103(2):177-84. PubMed PMID: 12455031.

159: Aparicio A, Weber JS. Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors. Curr Opin Investig Drugs. 2002 Apr;3(4):627-33. Review. PubMed PMID: 12090735.

160: Miller KB. Myelodysplastic syndromes. Curr Treat Options Oncol. 2000 Apr;1(1):63-9. Review. PubMed PMID: 12057062.

161: Kantarjian HM. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience. J Clin Oncol. 2002 May 15;20(10):2415-6. PubMed PMID: 12011118.

162: Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res. 2002 Feb 15;62(4):961-6. PubMed PMID: 11861364.

163: Matsuo T, Tomonaga M. [Chemotherapy and radiation therapy]. Nippon Rinsho. 2001 Dec;59(12):2364-8. Review. Japanese. PubMed PMID: 11766340.

164: Rodgers GP, Saunthararajah Y. Advances in experimental treatment of beta-thalassaemia. Expert Opin Investig Drugs. 2001 May;10(5):925-34. Review. PubMed PMID: 11322866.

165: Karpf AR, Moore BC, Ririe TO, Jones DA. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. Mol Pharmacol. 2001 Apr;59(4):751-7. PubMed PMID: 11259619.

166: Chang M, Raimondi SC, Ravindranath Y, Carroll AJ, Camitta B, Gresik MV, Steuber CP, Weinstein H. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. Leukemia. 2000 Jul;14(7):1201-7. PubMed PMID: 10914543.

167: Bovenzi V, Momparler RL. Quantitation of inhibition of DNA methylation of the retinoic acid receptor beta gene by 5-Aza-2'-deoxycytidine in tumor cells using a single-nucleotide primer extension assay. Anal Biochem. 2000 May 15;281(1):55-61. PubMed PMID: 10847610.

168: Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, Muse I, DiLeone L, Mans DR. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs. 2000 Feb;18(1):83-91. PubMed PMID: 10830142.

169: Lübbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol. 2000;249:135-64. Review. PubMed PMID: 10802943.

170: dos Santos NR, Torensma R, de Vries TJ, Schreurs MW, de Bruijn DR, Kater-Baats E, Ruiter DJ, Adema GJ, van Muijen GN, van Kessel AG. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res. 2000 Mar 15;60(6):1654-62. PubMed PMID: 10749136.

171: Quesnel B, Fenaux P. P15INK4b gene methylation and myelodysplastic syndromes. Leuk Lymphoma. 1999 Nov;35(5-6):437-43. Review. PubMed PMID: 10609781.

172: Wilhelm M, O'Brien S, Rios MB, Estey E, Keating MJ, Plunkett W, Sorenson M, Kantarjian HM. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leuk Lymphoma. 1999 Aug;34(5-6):511-8. PubMed PMID: 10492074.

173: Goldberg RM, Reid JM, Ames MM, Sloan JA, Rubin J, Erlichman C, Kuffel MJ, Fitch TR. Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2363-70. PubMed PMID: 9815635.

174: Kritz AD, Raptis G, Menendez-Botet C, Maslak P, Jakubowski A. Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia. Am J Hematol. 1996 Feb;51(2):117-21. PubMed PMID: 8579051.

175: Manetta A, Blessing JA, Mann WJ, Smith DM. A phase II study of fazarabine (NSC 281272) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Am J Clin Oncol. 1995 Oct;18(5):439-40. PubMed PMID: 7572764.

176: Londei T, Mistò R, Vismara C, Leone VG. Congenital brain damage spares the basic patterns of parental behavior in affected mice. Brain Res. 1995 Apr 17;677(1):61-8. PubMed PMID: 7541698.

177: Rochette J, Craig JE, Thein SL. Fetal hemoglobin levels in adults. Blood Rev. 1994 Dec;8(4):213-24. Review. PubMed PMID: 7534152.

178: Lenzi R, Frost P, Abbruzzese JL. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines. Anticancer Res. 1994 Jan-Feb;14(1A):247-51. PubMed PMID: 7513143.

179: Côté S, Momparler RL. Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells. Anticancer Drugs. 1993 Jun;4(3):327-33. PubMed PMID: 7689364.

180: Gattei V, Aldinucci D, Petti MC, Da Ponte A, Zagonel V, Pinto A. In vitro and in vivo effects of 5-aza-2'-deoxycytidine (Decitabine) on clonogenic cells from acute myeloid leukemia patients. Leukemia. 1993 May;7 Suppl 1:42-8. PubMed PMID: 7683356.

181: Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, Demakos EP, Cornell CJ Jr, Carey RW, Schiffer C, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993 May;7 Suppl 1:21-9. PubMed PMID: 7683352.

182: Momparler RL, Doré BT, Labiberté J, Momparler LF. Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase. Leukemia. 1993 May;7 Suppl 1:17-20. PubMed PMID: 7683351.

183: Ben-Baruch N, Denicoff AM, Goldspiel BR, O'Shaughnessy JA, Cowan KH. Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer. Invest New Drugs. 1993 Feb;11(1):71-4. PubMed PMID: 7688714.

184: Clavel M, Monfardini S, Fosså S, Smyth J, Renard J, Kaye SB. 5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group. Ann Oncol. 1992 May;3(5):399-400. PubMed PMID: 1377488.

185: Hubbard KP, Daugherty K, Ajani JA, Pazdur R, Levin B, Abbruzzese JL. Phase II trial of fazarabine in advanced colorectal carcinoma. Invest New Drugs. 1992 Apr;10(1):39-42. PubMed PMID: 1376722.

186: Stamatoyannopoulos JA, Nienhuis AW. Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies. Annu Rev Med. 1992;43:497-521. Review. PubMed PMID: 1374600.

187: Steuber CP, Holbrook T, Camitta B, Land VJ, Sexauer C, Krischer J. Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study. Invest New Drugs. 1991 May;9(2):181-4. PubMed PMID: 1714886.

188: Bailey H, Tutsch KD, Arzoomanian RZ, Tombes MB, Alberti D, Bruggink J, Wilding G. Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. Cancer Res. 1991 Feb 15;51(4):1105-8. PubMed PMID: 1705165.

189: Hassan HT, Veit A, Maurer HR. Synergistic interactions between differentiation-inducing agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic micro assays. J Cancer Res Clin Oncol. 1991;117(3):227-31. PubMed PMID: 1709642.

190: Frost P, Abbruzzese JL, Hunt B, Lee D, Ellis M. Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. Cancer Res. 1990 Aug 1;50(15):4572-7. PubMed PMID: 1695122.

191: Jehn U. New approaches in the treatment of MDS: an overview of current trials. Acta Haematol Pol. 1990 Jul-Dec;21(2):129-38. PubMed PMID: 1719727.

192: Surbone A, Ford H Jr, Kelley JA, Ben-Baruch N, Thomas RV, Fine R, Cowan KH. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272). Cancer Res. 1990 Feb 15;50(4):1220-5. PubMed PMID: 1688736.

193: Sessa C, ten Bokkel Huinink W, Stoter G, Renard J, Cavalli F. Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group. Eur J Cancer. 1990 Feb;26(2):137-8. PubMed PMID: 1691012.

194: Charache S. Fetal hemoglobin, sickling, and sickle cell disease. Adv Pediatr. 1990;37:1-31. Review. PubMed PMID: 1702260.

195: Jehn U, Heinemann V. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia. Haematol Blood Transfus. 1990;33:333-8. PubMed PMID: 1691134.

196: Jehn U, Zittoun R, Suciu S, Fiere D, Haanen C, Peetermans M, Löwenberg B, Willemze R, Solbu G, Stryckmans P. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group. Haematol Blood Transfus. 1990;33:277-84. PubMed PMID: 1691132.

197: Rees JK, Gray RG. Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study. Haematol Blood Transfus. 1990;33:243-8. PubMed PMID: 1691131.

198: Lampkin BC, Woods WG, Buckley JD, Hammond GD. Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report. Haematol Blood Transfus. 1990;33:210-4. PubMed PMID: 1691130.

199: Heideman RL, Gillespie A, Ford H, Reaman GH, Balis FM, Tan C, Sato J, Ettinger LJ, Packer RJ, Poplack DG. Phase I trial and pharmacokinetic evaluation of fazarabine in children. Cancer Res. 1989 Sep 15;49(18):5213-6. PubMed PMID: 2475244.

200: Dover GJ, Charache S. Chemotherapy and hemoglobin F synthesis in sickle cell disease. Ann N Y Acad Sci. 1989;565:222-7. Review. PubMed PMID: 2476061.

201: Grem JL, Shoemaker DD, Hoth DF, King SA, Plowman J, Zaharko D, Grieshaber CK, Harrison SD Jr, Cradock JC, Leyland-Jones B. Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials. Invest New Drugs. 1987 Dec;5(4):315-28. Review. PubMed PMID: 2449402.

202: Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol. 1987 Dec;23(12):1921-4. PubMed PMID: 2449354.

203: Glover AB, Leyland-Jones BR, Chun HG, Davies B, Hoth DF. Azacitidine: 10 years later. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):737-46. Review. PubMed PMID: 2440570.

204: Dover GJ, Charache S. Increasing fetal hemoglobin production in sickle cell disease: results of clinical trials. Prog Clin Biol Res. 1987;251:455-66. PubMed PMID: 2448813.

205: Rees JK, Gray R, Hayhoe FG. The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia. Haematol Blood Transfus. 1987;30:35-7. PubMed PMID: 2442075.

206: Marcus RE, Catovsky D, Prentice HG, Newland AC, Chessells JM, Stevens RF, Hann IM, Goldman JM, Hoffbrand AV, Galton DA. Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985. Haematol Blood Transfus. 1987;30:346-51. PubMed PMID: 2442074.

207: van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 1986 Sep;46(9):4831-6. PubMed PMID: 2425959.

208: Kalwinsky DK, Dahl GV, Mirro J, Jackson CW, Look AT. Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine. Med Pediatr Oncol. 1986;14(5):245-50. PubMed PMID: 2431255.

209: Chabot GG, Momparler RL. Effects of 5-aza-2'-deoxycytidine on survival and cell cycle progression of L1210 leukemia cells. Leuk Res. 1986;10(5):533-7. PubMed PMID: 2423812.

210: Schiffer CA, Anderson K, Coleman M, Cuttner J. Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azacitidine administered by continuous infusion: a Cancer and Leukemia group B Study. Cancer Treat Rep. 1985 Sep;69(9):1027-8. PubMed PMID: 2411402.

211: Curt GA, Kelley JA, Fine RL, Huguenin PN, Roth JS, Batist G, Jenkins J, Collins JM. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880). Cancer Res. 1985 Jul;45(7):3359-63. PubMed PMID: 2408749.

212: Jehn U, Zittoun R. [AML-6 study of the value of cyclic alternating chemotherapy during remission in acute myelocytic leukemia]. Onkologie. 1985 Apr;8(2):94-5. German. PubMed PMID: 2582325.

213: Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther. 1985;30(3):277-86. PubMed PMID: 2433702.

214: Dover GJ, Humphries RK, Young N, Ley T, Boyer S, Charache S, Nienhuis A. Pharmacologic manipulation of fetal hemoglobin synthesis. Prog Clin Biol Res. 1985;191:447-54. PubMed PMID: 2413480.

215: Dover GJ, Charache S, Nora R, Boyer SH. Progress toward increasing fetal hemoglobin production in man: experience with 5-azacytidine and hydroxyurea. Ann N Y Acad Sci. 1985;445:218-24. PubMed PMID: 2409873.

216: Carella AM, Santini G, Martinengo M, Nati S, Giordano D, Congiu A, Cerri R, Damasio E, Risso M, Rossi E, et al. Amsacrine alone or in combination with 5-azacytidine and etoposide in refractory or relapsed acute non lymphoblastic leukemia (ANLL). Haematologica. 1985 Jan-Feb;70(1):39-43. PubMed PMID: 2408974.

217: Vogler WR, Winton EF, Gordon DS, Raney MR, Go B, Meyer L. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial. Blood. 1984 May;63(5):1039-45. PubMed PMID: 6201211.

218: Robak T. [Clinical pharmacology of 5-azacytidine]. Pol Tyg Lek. 1984 Feb 13;39(7):215-8. Polish. PubMed PMID: 6205386.

219: Heller P, DeSimone J. 5-Azacytidine and fetal hemoglobin. Am J Hematol. 1984;17(4):439-47. Review. PubMed PMID: 6208778.

220: Benz EJ Jr. Molecular genetics of the sickling syndromes: evolution of new strategies for improved diagnosis. Am J Pediatr Hematol Oncol. 1984 Spring;6(1):59-66. PubMed PMID: 6201079.

221: Gaynon PS, Baum ES. Continuous infusion of 5-azacytidine as induction for acute nonlymphocytic leukemia in patients with previous exposure to 5-azacytidine. Oncology. 1983;40(3):192-4. PubMed PMID: 6189042.

222: Ellims PH. Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal. Cancer Chemother Pharmacol. 1982 Dec;10(1):1-6. Review. PubMed PMID: 6186411.

223: Look AT, Dahl GV, Kalwinsky D, Senzer N, Mason C, Rivera G. Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine. Cancer Treat Rep. 1981 Nov-Dec;65(11-12):995-9. PubMed PMID: 6170431.

224: Holiat SM, Smith WE, Hubert DD, Davis S. Chemotherapeutic trials with hamster mesothelioma 10-24: responses to azacitidine, aziridinylbenzoquinone, cisplatin, and PCNU. Cancer Treat Rep. 1981 Nov-Dec;65(11-12):1113-5. PubMed PMID: 6170430.

225: Saiki JH, Bodey GP, Hewlett JS, Amare M, Morrison FS, Wilson HE, Linman JW. Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study. Cancer. 1981 Apr 1;47(7):1739-42. PubMed PMID: 6164472.

226: Chard RL Jr. Studies with anthracyclines in pediatric acute nonlymphocytic leukemia. Cancer Treat Rep. 1981;65 Suppl 4:77-81. PubMed PMID: 6179617.

227: Momparler RL, Frith CH. Toxicology in mice of the antileukemic agent 5-aza-2'-deoxycytidine. Drug Chem Toxicol. 1981;4(4):373-81. PubMed PMID: 6178576.

228: Cabanillas F. [Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)]. Sangre (Barc). 1981;26(5B):885-9. Spanish. PubMed PMID: 6172860.

229: Nitschke R, Land V, Steuber CP, Ragab AH. Low response rate to 5 aza-cytidine, vincristine, and prednisone therapy in previously treated childhood acute nonlymphocytic leukemia: a Southwest Oncology Group Study. Am J Pediatr Hematol Oncol. 1981 Fall;3(3):307-9. PubMed PMID: 6169289.

230: Peterson BA, Collins AJ, Vogelzang NJ, Bloomfield CD. 5-Azacytidine and renal tubular dysfunction. Blood. 1981 Jan;57(1):182-5. PubMed PMID: 6160887.

231: Lomen PL, Khilanani P, Kessel D. Phase I study using combination of hydroxyurea and 5-azacytidine (NSC-102816). Neoplasma. 1980;27(1):101-6. PubMed PMID: 6154898.

232: Cassileth PA, Petrillo MH, Cooper RA, Katz ME. Feasibility and efficacy of 5-azacytidine used early in the therapy of adult acute nonlymphocytic leukemia: an ECOG pilot study. Cancer Clin Trials. 1979 Winter;2(4):339-43. PubMed PMID: 93983.

233: Cavalli F, Brunner KW. [New substances in oncologic therapy]. Dtsch Med Wochenschr. 1978 Jul 7;103(27):1087-92. German. PubMed PMID: 78789.

234: Armitage JO, Burns CP. Treatment of refractory adult acute nonlymphoblastic leukemia with subcutaneous 5-azacytidine. Cancer Treat Rep. 1977 Dec;61(9):1721-3. PubMed PMID: 74285.

235: Vélez-Garcia E, Vogler WR, Bartolucci AA, Arkun SN. Twice weekly 5-azacytidine infusion in dissmeinated metastatic cancer: a phase II study. Cancer Treat Rep. 1977 Dec;61(9):1675-7. PubMed PMID: 74283.

236: Omura GA. Combination therapy with 5-azacytidine plus beta-2'-deoxythioguanosine in adult acute leukemia. Cancer Treat Rep. 1977 Aug;61(5):915-7. PubMed PMID: 70273.

237: Veselý J, Cihák A. [Possibilities for the clinical use of 5-azacytidine]. Vopr Onkol. 1977;23(10):65-73. Review. Russian. PubMed PMID: 74127.

238: Weiss AJ, Metter GE, Nealon TF, Keanan JP, Ramirez G, Swaiminathan A, Fletcher WS, Moss SE, Manthei RW. Phase II study of 5-azacytidine in solid tumors. Cancer Treat Rep. 1977 Jan-Feb;61(1):55-8. PubMed PMID: 67894.

239: Vogler WR, Miller DS, Keller JW. 5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia. Blood. 1976 Sep;48(3):331-7. PubMed PMID: 60156.

240: Shnider BI, Baig M, Colsky J. A phase I study of 5-azacytidine (NSC-102816). J Clin Pharmacol. 1976 Apr;16(4):205-12. PubMed PMID: 57124.

241: Lomen PL, Baker LH, Neil GL, Samson MK. Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days. Cancer Chemother Rep. 1975 Nov-Dec;59(6):1123-6. PubMed PMID: 56988.

242: Levi JA, Wiernik PH. Combination therapy with 5-azacytidine (NSC-102816) and methyl-GAG (NSC-32946) in previously treated adults with acute nonlymphocytic leukemia. Cancer Chemother Rep. 1975 Sep-Oct;59(5):1043-5. PubMed PMID: 54215.

243: Vogler WR, Arkun S, Velez-Garcia E. Phase I study of twice weekly 5-azacytidine (NSC-102816). Cancer Chemother Rep. 1974 Nov-Dec;58(6):895-9. PubMed PMID: 4141280.

244: Bellet RE, Mastrangelo MJ, Engstrom PF, Strawitz JG, Weiss AJ, Yarbro JW. Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816). Cancer Chemother Rep. 1974 Mar-Apr;58(2):217-22. PubMed PMID: 4133839.

245: McCredie KB, Bodey GP, Burgess MA, Gutterman JU, Rodriguez V, Sullivan MP, Freireich EJ. Treatment of acute leukemia with 5-azacytidine (NSC-102816). Cancer Chemother Rep. 1973 Sep-Oct;57(3):319-23. PubMed PMID: 4127393.

246: Karon M, Sieger L, Leimbrock S, Finklestein JZ, Nesbit ME, Swaney JJ. 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood. 1973 Sep;42(3):359-65. PubMed PMID: 4125239.

247: Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep. 1972 Oct;56(5):649-52. PubMed PMID: 4119908.